Centessa Pharmaceuticals PLC
CNTAHealthcare|Biotechnology|UK
$40.50
+0.00 (+0.00%)
Tangible Book
$3.15
Earnings Power
$1.77
Clinical Trials (17)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07598708 A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence | Narcolepsy Type 1, Narcolepsy Type 2 | P2P3 | Recruiting | 222 | RCT, Double-blind | cleminorexton, Placebo |
| NCT06752668 A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia | Narcolepsy Type 1, Narcolepsy Type 2 | P2 | Recruiting | 248 | RCT, Double-blind | ORX750, Placebo |
| NCT07096674 A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia | Narcolepsy Type 1, Narcolepsy Type 2 | P2 | Recruiting | 90 | Open-label | ORX750, ORX750, ORX750 |
| NCT07413666 A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years | Healthy Adult Male and Female Volunteers | P1 | Recruiting | 212 | RCT, Double-blind | ORX489 Tablets |
| NCT07082829 A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age | Excessive Daytime Sleepiness | P1 | Recruiting | 208 | RCT, Double-blind | ORX142 Tablets |
| NCT04152837 Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease | Polycystic Kidney Disease, Adult, ADPKD | P3 | Terminated | 7 | Open-label | Lixivaptan |
| NCT06568302 The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial | Hemophilia a, Hemophilia B | P3 | Terminated | 15 | Open-label | SerpinPC |
| NCT05208866 Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303 | Polycystic Kidney Disease, Adult | P3 | Terminated | 1 | Open-label | Lixivaptan |
| NCT04064346 Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease | Autosomal Dominant Polycystic Kidney, ADPKD | P3 | Terminated | 12 | RCT, Double-blind | Lixivaptan, Placebo |
| NCT05821777 A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors | Advanced Solid Tumor | P1P2 | Terminated | 25 | Open-label | LB101 |
| NCT05789537 A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors | Hemophilia B with Inhibitor, Hemophilia B | P2 | Terminated | 3 | Open-label | SerpinPC |
| NCT04985825 Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | P2 | Withdrawn | — | Open-label | Imgatuzumab |
| NCT04073498 The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B) | Hemophilia a, Hemophilia B | P1P2 | Completed | 39 | Single-blind | SerpinPC, Placebo |
| NCT05789524 The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B | Hemophilia a, Hemophilia B | P2 | Terminated | 60 | RCT, Open-label | SerpinPC |
| NCT05323110 Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers | Chronic Inflammatory Disease | P1 | Terminated | 56 | RCT, Double-blind | CBS001, Placebo |
| NCT04443192 A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiXZ Subjects | Alpha1 Anti-Trypsin Deficiency | P1 | Terminated | 69 | RCT, Double-blind | ZF874, Placebo |
| NCT05605678 Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5) | Hemophilia a, Hemophilia B | Terminated | 108 | — | — |